fig1

Figure 1. Relative abundances of (A) gut and (B) oral microbiota profiles showed little changes throughout the study treatment, thereby indicating that pembrolizumab and eribulin do not confer microbiota toxicity; (C) There were 57 common genera between the oral and gut microbiota profiles.